Bibliography: library/10665-331525-rus

The reference for library/10665-331525-rus (who-iris) and any references extracted from it. library · All references.

WHO. WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment.

Title
WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment
Authors
WHO
Issued
D:20210920
Type
document

Sources

No link to the work is recorded for this reference.

In the knowledge graph

  • IRI references/10665-331525-rus
  • provenance: library
  • read from library/10665-331525-rus/manifest.jsonld (who-iris, sub-graph library)
  • library copy: library/10665-331525-rus

Export: BibTeX · RIS · CSL-JSON · DC XML

Export these 119 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

119 shown

  1. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
    · extracted · source: references/10665-331525-rus.page-158.1.json
  2. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (http://www.who.int/tb/publications/global_report/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.10.json
  3. Priftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.100.json
  4. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
    · extracted · source: references/10665-331525-rus.page-158.101.json
  5. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–66.
    · extracted · source: references/10665-331525-rus.page-158.102.json
  6. Pellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000 (https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.103.json
  7. Nursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.104.json
  8. William JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41.
    · extracted · source: references/10665-331525-rus.page-158.105.json
  9. HIV drug interaction checker. University of Liverpool [веб-сайт] (https://www.hiv-druginteractions.org/checker, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.106.json
  10. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/AIDS. World Health Organization [веб-сайт]; 2018 (https://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/ accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.107.json
  11. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
    · extracted · source: references/10665-331525-rus.page-158.108.json
  12. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7.
    · extracted · source: references/10665-331525-rus.page-158.109.json
  13. Политическая декларация заседания высокого уровня Генеральной Ассамблеи по борьбе с туберкулезом. Семьдесят третья сессия Генеральной ассамблеи ООН; 2018 https://undocs.org/ru/A/RES/73/3, по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.11.json
  14. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
    · extracted · source: references/10665-331525-rus.page-158.110.json
  15. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
    · extracted · source: references/10665-331525-rus.page-158.111.json
  16. Dooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (https://www.croiconference.org/abstract/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.112.json
  17. López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681–90.
    · extracted · source: references/10665-331525-rus.page-158.113.json
  18. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
    · extracted · source: references/10665-331525-rus.page-158.114.json
  19. Faren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.115.json
  20. Medication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences (https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.116.json
  21. Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
    · extracted · source: references/10665-331525-rus.page-158.117.json
  22. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
    · extracted · source: references/10665-331525-rus.page-158.118.json
  23. WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.12.json · held: library/10665-331170
  24. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.13.json
  25. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
    · extracted · source: references/10665-331525-rus.page-158.14.json
  26. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
    · extracted · source: references/10665-331525-rus.page-158.15.json
  27. Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
    · extracted · source: references/10665-331525-rus.page-158.16.json
  28. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
    · extracted · source: references/10665-331525-rus.page-158.17.json
  29. Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.18.json
  30. Bruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
    · extracted · source: references/10665-331525-rus.page-158.19.json
  31. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
    · extracted · source: references/10665-331525-rus.page-158.2.json
  32. Cotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
    · extracted · source: references/10665-331525-rus.page-158.20.json
  33. Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
    · extracted · source: references/10665-331525-rus.page-158.21.json
  34. Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
    · extracted · source: references/10665-331525-rus.page-158.22.json
  35. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
    · extracted · source: references/10665-331525-rus.page-158.23.json
  36. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–7.
    · extracted · source: references/10665-331525-rus.page-158.24.json
  37. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–44.
    · extracted · source: references/10665-331525-rus.page-158.25.json
  38. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
    · extracted · source: references/10665-331525-rus.page-158.26.json
  39. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
    · extracted · source: references/10665-331525-rus.page-158.27.json
  40. Chaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis. 2010;201(5):653–5.
    · extracted · source: references/10665-331525-rus.page-158.28.json
  41. Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrent-tuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.29.json
  42. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.
    · extracted · source: references/10665-331525-rus.page-158.3.json
  43. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (https://www.who.int/tb/tbscreening/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.30.json
  44. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/contact_investigation2012/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.31.json
  45. WHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.32.json
  46. Политика ВОЗ в отношении сотрудничества в области ТБ/ВИЧ. Руководящие принципы для национальных программ и других заинтересованных сторон. Женева: Всемирная организация здравоохранения; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng_Annexes.pdf, по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.33.json
  47. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140–156.
    · extracted · source: references/10665-331525-rus.page-158.34.json
  48. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–368.
    · extracted · source: references/10665-331525-rus.page-158.35.json
  49. Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020; 70(3):425–35.
    · extracted · source: references/10665-331525-rus.page-158.36.json
  50. Lung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–84.
    · extracted · source: references/10665-331525-rus.page-158.37.json
  51. Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
    · extracted · source: references/10665-331525-rus.page-158.38.json
  52. Prevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization; 2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.39.json
  53. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8.
    · extracted · source: references/10665-331525-rus.page-158.4.json
  54. Обновленное сводное руководство по программному ведению случаев латентной туберкулезной инфекции. Женева: Всемирная организация здравоохранения; 2018 (http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/, по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.40.json
  55. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (who.int/tb/publications/chest-radiography/en/, accessed 15 March 2020).
    · extracted · source: references/10665-331525-rus.page-158.41.json
  56. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
    · extracted · source: references/10665-331525-rus.page-158.42.json
  57. TB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.43.json
  58. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000171.pub3/abstract, accessed 15 March 2020).
    · extracted · doi:10.1002/14651858.CD000171.pub3/abstract · source: references/10665-331525-rus.page-158.44.json
  59. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
    · extracted · source: references/10665-331525-rus.page-158.45.json
  60. Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
    · extracted · source: references/10665-331525-rus.page-158.46.json
  61. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, accessed 16 March 2020).
    · extracted · doi:10.1002/14651858.CD007545.pub2 · source: references/10665-331525-rus.page-158.47.json
  62. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
    · extracted · source: references/10665-331525-rus.page-158.48.json
  63. Руководство по ведению пациентов с латентной туберкулезной инфекцией. Женева: Всемирная организация здравоохранения; 2015 (https://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf, по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.49.json
  64. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
    · extracted · source: references/10665-331525-rus.page-158.5.json
  65. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.50.json
  66. January 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.51.json
  67. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
    · extracted · source: references/10665-331525-rus.page-158.52.json
  68. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15.
    · extracted · source: references/10665-331525-rus.page-158.53.json
  69. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
    · extracted · source: references/10665-331525-rus.page-158.54.json
  70. Landmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019. Unitaid [веб-сайт] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-price-of-medicine- to-prevent-tb/#en, accessed 16 March 2020.
    · extracted · link · source: references/10665-331525-rus.page-158.55.json
  71. Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising concepts. Tuberculosis. 2015;95(4):373–84.
    · extracted · source: references/10665-331525-rus.page-158.56.json
  72. Catalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP and 3RH. Technical Brief. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/catalyzing-pediatric-tuberculosis-innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.57.json
  73. TPT implementation tools. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/3hp-documents/, по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.58.json
  74. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
    · extracted · source: references/10665-331525-rus.page-158.59.json
  75. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol. 2011;40(4):964–70.
    · extracted · source: references/10665-331525-rus.page-158.6.json
  76. Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc. 1954;70(3):430–41.
    · extracted · source: references/10665-331525-rus.page-158.60.json
  77. Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc. 1954;70(3):504–8.
    · extracted · source: references/10665-331525-rus.page-158.61.json
  78. Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
    · extracted · source: references/10665-331525-rus.page-158.62.json
  79. Money GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
    · extracted · source: references/10665-331525-rus.page-158.63.json
  80. Toman K, Frieden TR. Toman’s tuberculosis: case detection, treatment and monitoring; questions and answers. 2nd edition. Geneva: World Health Organization; 2004.
    · extracted · source: references/10665-331525-rus.page-158.64.json
  81. McCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
    · extracted · source: references/10665-331525-rus.page-158.65.json
  82. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8.
    · extracted · source: references/10665-331525-rus.page-158.66.json
  83. Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
    · extracted · source: references/10665-331525-rus.page-158.67.json
  84. Sotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3.
    · extracted · source: references/10665-331525-rus.page-158.68.json
  85. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64.
    · extracted · source: references/10665-331525-rus.page-158.69.json
  86. Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт] (http://www.who.int/tb/strategy/en/ по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.7.json
  87. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. 1970;101(5):780–2.
    · extracted · source: references/10665-331525-rus.page-158.70.json
  88. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
    · extracted · source: references/10665-331525-rus.page-158.71.json
  89. Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93.
    · extracted · source: references/10665-331525-rus.page-158.72.json
  90. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
    · extracted · source: references/10665-331525-rus.page-158.73.json
  91. Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017 (http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.74.json
  92. Leveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated Service Delivery [Supplement]. Geneva: International AIDS Society (https://differentiatedservicedelivery.org/Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.75.json
  93. Differentiated models of delivering HIV care: Perspectives from people living with HIV and health care workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service delivery [веб-сайт] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care//, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.76.json
  94. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9.
    · extracted · source: references/10665-331525-rus.page-158.77.json
  95. Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9.
    · extracted · source: references/10665-331525-rus.page-158.78.json
  96. Isoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.79.json
  97. Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт]; 2013 (https://www.who.int/tb/post2015_strategy/en/ по состоянию на 31 марта 2021 г.).
    · extracted · link · source: references/10665-331525-rus.page-158.8.json
  98. Rifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.80.json
  99. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
    · extracted · source: references/10665-331525-rus.page-158.81.json
  100. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–41.
    · extracted · source: references/10665-331525-rus.page-158.82.json
  101. Partosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
    · extracted · source: references/10665-331525-rus.page-158.83.json
  102. Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/cid/ciz863, accessed 18 March 2020).
    · extracted · doi:10.1093/cid/ciz863 · source: references/10665-331525-rus.page-158.84.json
  103. Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
    · extracted · source: references/10665-331525-rus.page-158.85.json
  104. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
    · extracted · source: references/10665-331525-rus.page-158.86.json
  105. McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028–34.
    · extracted · source: references/10665-331525-rus.page-158.87.json
  106. Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
    · extracted · source: references/10665-331525-rus.page-158.88.json
  107. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
    · extracted · source: references/10665-331525-rus.page-158.89.json
  108. Framework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization; 2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.9.json
  109. Ahmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really matter? Clin Liver Dis. 2017;10(5):111–5.
    · extracted · source: references/10665-331525-rus.page-158.90.json
  110. Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7; AAC.01215–19. doi: 10.1128/AAC.01215–19, accessed 18 March 2020).
    · extracted · doi:10.1128/AAC.01215–19 · source: references/10665-331525-rus.page-158.91.json
  111. Friedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
    · extracted · source: references/10665-331525-rus.page-158.92.json
  112. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
    · extracted · source: references/10665-331525-rus.page-158.93.json
  113. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72–82.
    · extracted · source: references/10665-331525-rus.page-158.94.json
  114. Mike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection//, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525-rus.page-158.95.json
  115. Aquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
    · extracted · source: references/10665-331525-rus.page-158.96.json
  116. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
    · extracted · source: references/10665-331525-rus.page-158.97.json
  117. Weiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
    · extracted · source: references/10665-331525-rus.page-158.98.json
  118. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
    · extracted · source: references/10665-331525-rus.page-158.99.json
  119. WHO. WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment.
    10665-331525-rus · library · source: library/10665-331525-rus/manifest.jsonld · held: library/10665-331525-rus
    export: BibTeX · RIS · CSL-JSON · DC XML